SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards as the community discusses concerns around its leveraged Bitcoin position and potential forced selling if Bitcoin prices continue to fall. News of a newly established USD reserve and updates to FY25 guidance have fueled debates about the company's financial strategy and future prospects. Investors are expressing bearish sentiment, questioning the stock's premium over its net asset value and the impact of potential dilution.

Fly-E Group, Inc. is an electric vehicle company, which engages in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the brand Fly E-Bike. Its products include electric-scooter, e-bikes, parts, and accessories. The company was founded by Zhou Ou in 2018 and is headquartered in Flushing, NY.

Fly-E Group Inc.

Fly-E Group Inc

FLYE is trending due to a massive intraday price swing, leaving community members speculating about the cause and potential for a short squeeze. Chatter suggests comparisons to similar low-float runners and potential connections to market manipulation, while others are focused on whether the company will address the volatility. The stock's volatile price action and recent news are fueling active discussions among investors.

Ambitions Enterprise Management Co LLC

AHMA is trending amid discussions of low float IPOs potentially making a comeback, drawing comparisons to SMX. The stock experienced halts and volatile price action, leading to community debate about support levels and potential overstays. Some traders are also noting potential catalysts and comparing it to other trending tickers like QTTB.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is trending as investors discuss a potential government equity stake for national security reasons and weigh the implications of the company's recent emergence from Chapter 11. Community members are debating the stock's valuation, with some pointing to its revenue, assets, and potential for a short squeeze, while others remain skeptical due to past losses and dilution.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust ($SLV) is trending as silver prices surge to new all-time highs, sparking community excitement about a potential squeeze. Discussions revolve around silver's strong industrial demand from AI and EV sectors, a possible supply shortage, and its potential as a safe haven amid crypto market volatility. Some traders are also debating whether physical silver is a better investment than $SLV.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards as the community discusses potential price drops and its correlation with MicroStrategy's holdings ($MSTR). Concerns about market manipulation, regulatory pressures, and comparisons to traditional assets like gold and silver are fueling bearish sentiment. Traders are closely watching key support levels amid speculation about a deeper correction.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid renewed interest from Michael Burry, who recently shared a 2019 email exchange with Roaring Kitty and hinted at releasing his full GME story soon. The community is closely watching for further updates and speculating on the potential impact of upcoming earnings, especially given the company's strong cash position and Bitcoin holdings. Discussions also involve short squeeze potential and the stock's volatile price action.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid a broader crypto market pullback, with community members debating the potential impact of upcoming events and expressing frustration with price volatility. Some traders are looking at XRP as a buying opportunity, while others suggest moving to other investments to offset losses. Discussions also include speculation about market manipulation and the influence of larger economic factors.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF (BTC) is trending amid market volatility, with Bitcoin experiencing price swings and community debates about potential bear traps and future price direction. Discussions include the impact of macroeconomic factors and institutional investments, alongside comparisons to other assets and sectors. Investors are also closely monitoring MicroStrategy's (MSTR) moves, given its substantial Bitcoin holdings and correlation to BTC's price.

Bullish Degen (BULLISH) is a community-driven meme token on Solana that represents the optimistic and risk-taking spirit of crypto culture. The project’s purpose is to unite holders around the shared mantra of “staying bullish” regardless of market conditions. Its utility is cultural and social: driving engagement through memes, community events, and digital identity as a “bullish degen” within the Solana ecosystem.

bullish

$BULLISH is gaining attention as buyers become more aggressive and the community anticipates a potential breakout, with some suggesting whales are accumulating. Discussions highlight its undervalued status and solid trend behavior, drawing comparisons to other memecoins like $USELESS and anticipating exchange listings.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.read more...

Q32 Bio Sells Complement Inhibitor ADX-097

Q32 Bio Sells Complement Inhibitor ADX-097 Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire WALTHAM, Mass., Dec. 1, 2025 -- Asset sale further enables Company's strategic focus on advancing...

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov...

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a...

Retail investor interest in Q32 Bio Inc picked up on Wednesday after the clinical-stage biotech said the U.S. Food and Drug Administration granted Fast Track designation to its experimental treatment for alopecia areata.The drug, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody being tested in a Phase 2 trial for alopecia areata (AA), an autoimmune disorder that causes hair loss.&nbsp;The Fast Track status is intended to speed development of therapies that address serious conditions and unmet medical needs."The Fast Track designation granted by the FDA recognizes the seriousness of AA and the significant current unmet medical need while underscoring bempikibart's potential as a novel, differentiated therapy," said Q32 Bio Chief Executive Jodie Morrison in a statement.Bempikibart is designed to re-regulate immune function by blocking IL-7 and TSLP signaling pathways, key components in autoimmune activity.&nbsp;The company recently began dosing patients in both an open-label extension and Part B of its SIGNAL-AA trial following encouraging early results.The FDA designation allows for more frequent meetings with the agency, eligibility for priority review, and the possibility of accelerated approval, subject to clinical results.On Stocktwits, 24-hour message volume for Regulus jumped by 1,600% amid bullish sentiment.Some users highlighted the stock’s low float and recent FDA news as drivers for a potential swing trade, while others noted that the therapy itself — bempikibart — is making steady clinical progress.&nbsp;<stembedurl>https://stocktwits.com/onlyfactshere/message/613083538</stembedurl>One user pointed to the Fast Track status as a key catalyst, potentially accelerating development timelines for a treatment area with few approved options.&nbsp;<stembedurl>https://stocktwits.com/ALOSETE/message/613089756</stembedurl>Still, some cautioned that despite promising Phase 2 data, the company’s limited cash runway — estimated at about five quarters — underscores the inherent risks of biotech investing.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/613078123</stembedurl>Shares of Q32 Bio have declined 1.9% year-to-date, underperforming the Nasdaq, which is down 1.6%, but faring better than the Dow and S&amp;P 500, which have fallen 4.1% and 5.1%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug

Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.

Equity

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio to Participate in Upcoming March Investor Conferences Q32 Bio to Participate in Upcoming March Investor Conferences PR Newswire WALTHAM, Mass., Feb. 26, 2025 WALTHAM, Mass., Feb. 26, 2025...

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in...

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference PR Newswire WALTHAM...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of its lead candidate, bempikibart (ADX-914).&nbsp;The clinical-stage biotech company is under heavy selling pressure, with retail sentiment turning ‘extremely bearish’ on Stocktwits amid a spike in message volume.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QTTB_sentiment_and_message_volume_on_Dec_11_5dea79b168.png" alt="QTTB sentiment and message volume on Dec 11.png" width="1318" height="324"><figcaption>QTTB sentiment and message volume on Dec 11 as of 8:30 am ET | source: Stocktwits</figcaption></figure>The SIGNAL-AA trial for alopecia areata showed “encouraging” clinical activity, with a mean reduction of 16% in the Severity of Alopecia Tool (SALT) score for bempikibart recipients versus 2% in the placebo group at 24 weeks.&nbsp;However, only 9% of bempikibart patients achieved SALT-20, compared to none in the placebo group.Meanwhile, the SIGNAL-AD trial for atopic dermatitis failed to meet its primary endpoint in Part B, with patients receiving bempikibart showing a 74% improvement in the Eczema Area and Severity Index at 14 weeks, compared to 76% in the placebo group.&nbsp;CEO Jodie Morrison expressed disappointment, citing plans to review the data to understand the high placebo rate and trial outcomes better.The mixed results prompted a series of downgrades:• Wells Fargo cut its rating to ‘Equal Weight’ from ‘Overweight’ and slashed its price target to $16 from $95, citing disappointing atopic dermatitis results and concerns over Q32’s cash needs.• Leerink lowered its rating to ‘Market Perform’ from ‘Outperform’, with a price target of $9, down from $68. The firm removed atopic dermatitis value from its model and noted uncertainty around alopecia areata progression.• Raymond James downgraded Q32 Bio to ‘Outperform’ from ‘Strong Buy’, with its price target falling to $22 from $90. Analyst Steven Seedhouse highlighted underestimated market reaction but acknowledged the potential of the IL7R-4 mechanism.• Oppenheimer reduced its price target to $20 from $80 while maintaining an ‘Outperform’ rating, citing the alopecia opportunity’s potential despite setbacks in atopic dermatitis.Despite the sharp decline, QTTB shares remain up over 120% year-to-date.&nbsp;However, near-term sentiment and confidence in the stock have been severely dented, with investors awaiting further clarity on the drug’s development plans.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Q32 Bio Stock Plunges After Analyst Downgrades, Price-Target Slashes Over Alopecia Data: Retail Confidence Drops

CEO Jodie Morrison expressed disappointment, citing plans to review the data to understand the high placebo rate and trial outcomes better

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing...

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

QTTB
Q32 Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QTTB News

QTTBQ32 Bio Inc.